| dc.contributor | Univ Mayor, Oncol, Santiago, Chile | es |
| dc.contributor.author | Rha, SY. | |
| dc.contributor.author | Wyrwicz, LS. | |
| dc.contributor.author | Weber, PEY. | |
| dc.contributor.author | Bai, Y. | |
| dc.contributor.author | Ryu, MH. | |
| dc.contributor.author | Lee, J. | |
| dc.contributor.author | Rivera, F. | |
| dc.contributor.author | Alves, GV. | |
| dc.contributor.author | Garrido, M. [Univ Mayor, Oncol, Santiago, Chile] | |
| dc.contributor.author | Shiu, KK. | |
| dc.contributor.author | González Fernández, M. | |
| dc.contributor.author | Li, J. | |
| dc.contributor.author | Lowery, M. | |
| dc.contributor.author | Cil, T. | |
| dc.contributor.author | Cruz, FJSM. | |
| dc.contributor.author | Qin, S. | |
| dc.contributor.author | Yin, L. | |
| dc.contributor.author | Bordia, S. | |
| dc.contributor.author | Bhagia, P. | |
| dc.contributor.author | Oh, DY | |
| dc.date.accessioned | 2024-03-20T21:12:04Z | |
| dc.date.available | 2024-03-20T21:12:04Z | |
| dc.date.issued | 2023-02 | |
| dc.identifier.citation | Rha, S. Y., Wyrwicz, L. S., Weber, P. E. Y., Bai, Y., Ryu, M. H., Lee, J., ... & Oh, D. Y. (2023). VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study. Annals of Oncology, 34(3), 319-320. | es |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.issn | eISSN 1569-8041 | |
| dc.identifier.other | WOS:000951375500001 | |
| dc.identifier.uri | https://repositorio.umayor.cl/xmlui/handle/sibum/9474 | |
| dc.identifier.uri | https://doi-org.bibliotecadigital.umayor.cl:2443/10.1016/j.annonc.2023.01.006 | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2023.01.006 | |
| dc.description.abstract | PD-1 inhibitors in combination with chemo have shown efficacy in G/GEJ cancer. We present results of the double-blind, placebo-controlled KEYNOTE-859 study of pembro + fluoropyrimidine- and platinum-containing chemo for advanced HER2-negative G/GEJ cancer (NCT03675737). | es |
| dc.description.sponsorship | Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. | es |
| dc.format.extent | 2 p., PDF | es |
| dc.language.iso | en_US | es |
| dc.publisher | ELSEVIER | es |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Chile | es |
| dc.title | Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study | es |
| dc.type | Artículo o Paper | es |
| umayor.indizador | COT | es |
| umayor.indexado | Web of Science | es |
| dc.identifier.doi | 10.1016/j.annonc.2023.01.006 | |
| umayor.indicadores.wos-(cuartil) | Q1 | |
| umayor.indicadores.scopus-(scimago-sjr) | SCIMAGO/ INDICE H: 277 | |
| umayor.indicadores.scopus-(scimago-sjr) | SJR 11,95 | |